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Antimicrobial activityAbstract A series of new quinazolinone derivatives have been synthesized. Elemental analysis, IR,
1H NMR and mass spectral data elucidated the structures of all newly synthesized compounds. In
vitro antimicrobial activities of the synthesized compounds were investigated against Gram-positive
Bacillus subtilis (ATCC No. 6633), Staphylococcus aureus (ATCC No. 25923), Gram-negative Sal-
monella typhimurium (ATCC No. 23564), Pseudomonas aeruginosa (ATCC No. 27853) and fungi
Candida albicans and Aspergillus niger. Among all the tested compounds, some of the tested com-
pounds showed equipotent activity with standard.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Quinazolinone is a building block for approximately 150 nat-
urally occurring alkaloids isolated to date from a number of
families of the plant kingdom, from animals and from micro-
organisms. Quinazolinone and its derivatives have also
attracted a widespread interest due to the diverse biological
activities associated with them. They are pharmaceutically
important as antituberculars (Satsangi, 1979), thromboxane
A2 synthetase inhibitors (Joshi and Chaudhari, 1987), antibac-
terial (Wright and Tomcufcik, 1987), antiparkinsons (Srivast-ava et al., 1987), antihelmintics (Gupta et al., 1988) and they
also show blood platelet anti-aggregating activity (Sakai and
Nahata, 1988). In the light of recent studies (Ma et al., 1997,
1999), it might be expected that a combination of quinolines
moiety with such structures may increase their biological activ-
ities or create new medicinal properties. It is worthy to men-
tion that the combination of this moiety, formulated a
unique structure, which showed different biological activities,
such as anti-tumor activity, cytotoxic toward the leukemia
P388 cells, etc. Quinoline is frequently integrated into an or-
ganic compound in order to have enhanced or unexpected bio-
logical activities.
Literature survey reveals that quinolines are synthetic anti-
bacterial drugs with potential activity against a wide spectrum
of signiﬁcant bacterial pathogens with resultant broad clinical
activity. However, resistance to quinolines is a common
phenomenon, so in order to meet this draw back synthesis of
new quinoline derivatives is envisaged. Quinolines are present
in a wide range of natural and unnatural compounds with
remarkable medicinal activities (Balasubramanian et al.,
Synthesis, characterization and antimicrobial screening of substituted quiazolinones derivatives 4751996; Michael, 2007). In this regard, quinolines have occupied
a unique position in the design and synthesis of novel biolog-
ically active compounds since they are often used as anti-
inﬂammatory, antiasthmatic, antituberculosis, antibacterial,
antihypertensive, antitumor and most notably, antimalarial
agents (Maguire et al., 1994; Larsen et al., 1996; Kalluraya
and Sreenivasa, 1998; Roma et al., 2000; Gabriele et al.,
2007). Although quinolines are among the most extensively
studied heterocyclic compounds, quinazolinone substituted
quinolines are not often found in the literature. Therefore,
the synthesis of quinazolinone derivatives directly linked to a
quinoline unit is of considerable interest since their properly
substituted analogues are biologically active and exist in the
structures of various antitumor agents (Craig, 1972; Atwell
et al., 1989).
General investigation also revealed that life threatening
infections caused by pathogenic microbes are becoming
increasingly common, especially in immuno-compromised
individuals, such as persons undergoing cancer chemotherapy
or AIDS patients. Antibacterial is a general term for drug,
chemical or other substance that either kills or slows the
growth of microbe. Bacteria is responsible for almost all of
the common infectious diseases and the need for new antibac-
terial agents is greater than ever because of the emergence of
multi drug resistance in common pathogens and the rapid
emergence of new infections.
So, in the course of our research work to search a new
potent and safe synthesis of biologically active heterocycles
(Mandhane et al., 2010; Joshi et al., 2010; Jadhav et al.,
2009; Diwakar et al., 2008), herein we report the ultrasound as-
sisted synthesis of various derivatives of quinoline incorporated
quinazolinones heterocycle and screen them for antimicrobial
activities.2. Experimental
2.1. Instruments
The melting points were determined on a Veego apparatus and
are uncorrected. The reactions were monitored by TLC. The
mass spectra were taken on a Macro mass spectrometer
(Waters). The IR spectra were recorded in Nujol on Schimatzu
8000 spectrophotometer. 1H NMR spectra were recorded on a
Bruker 400 MHz instrument in DMSO and TMS as an inter-
nal standard. Elemental analysis was performed on Perkin–
Elmer EAL-240 elemental analyzers.
2.2. Procedure
2.2.1. 2-Chloroquinoline-3-carbaldehyde (1a)
The compound 1a was prepared as per procedure reported in
Meth-Cohn et al. (1981). Yield 79%, m.p. 148 C; IR-(KBr):
2739, 1710, 1605 and 755 cm1; 1H NMR-(DMSO-d6): d
10.36 (s, 1H), 8.57 (s, 1H), 8.06 (d, 1H), 7.92 (m, 2H), 7.75
(dd, 1H); MS: m/z 192.3 (M+); Elemental analysis:
C10H6ClNO Calcd.: C, 62.68; H, 3.16; N, 7.31; O, 8.35; found
C, 62.74; H, 3.21; N, 7.20; O, 8.31.
2.2.2. Synthesis of 2-(p-tolyloxy)quinoline-3-carbaldehyde (2a)
To a mixture of p-cresol (0.031 mmol, 3.38 g) and K2CO3
(0.068 mmol, 9.51 g) in DMF, compound 1a (0.031 mmol,6 g) was added and the reaction mixture was stirred at 85–
90 C for 5 h. The completion of the reaction was monitored
by TLC. After completion, water (50 ml) was poured in the
reaction mixture and the solid thus obtained was ﬁltered off
and recrystallized from ethyl acetate. Yield 80%, m.p.
128 C; IR-(KBr): 2945, 2750, 1720, 1600 and 1225 cm1; 1H
NMR-(DMSO-d6): d 10.65 (s, 1H), 8.71 (s, 1H), 7.88 (d,
1H), 7.74 (d, 1H), 7.71 (m, 1H), 7.45 (m, 1H), 7.39 (d, 2H),
7.19 (d, 2H), 2.41 (s, 3H); MS: m/z 264.1 (M+); Elemental
analysis: C17H13NO2 Calcd.: C, 77.55; H, 4.98; N, 5.32; O,
12.15; found C, 77.63; H, 5.01; N, 5.21; O, 12.09.
2.2.3. Synthesis of (2-chloroquinolin-3-yl)methanol (3a)
To a mixture of compound 2a in methanol, sodium borohy-
dride was added portion wise, and the mixture was stirred at
room temperature for 15–20 min. The completion of the reac-
tion was monitored by TLC and reaction mass was concen-
trated under vacuum. The reaction mass was poured into ice
cold water and solid thus obtained was ﬁltered and recrystal-
lized from ethyl acetate.
2.2.3.1. (2-Chloroquinolin-3-yl)methanol (3a). Yield 94%,
m.p. 168 C; IR-(KBr): 2945, 2750, 1600 and 1125 cm1; 1H
NMR-(DMSO-d6): d 8.21 (s, 1H), 8.18 (dd, 1H), 7.91 (m,
1H), 7.82 (dd, 1H), 7.51 (dd, 1H), 4.96 (s, 2H), 3.75 (s, 1H);
MS: m/z 193.9 (M+); Elemental analysis: C10H8ClNO Calcd.:
C, 62.03; H, 4.16; N, 7.23; O, 8.26; found C, 62.21; H, 4.19; N,
7.18; O, 8.21.
2.2.4. 2-(p-Tolyloxy)quinolin-3ylmethanol (3f)
Yield 77%, m.p. 120 C; IR-(KBr): 3427, 2920, 1520 and
1225 cm1; 1H NMR-(DMSO-d6): d 8.05 (s, 1H), 7.62 (d,
1H), 7.48 (d, 2H), 7.41 (d, 1H), 7.25 (dd, 2H), 7.23 (d, 2H),
4.74 (s, 2H), 4.01 (s, 1H), 3.51 (s, 1H), 2.46 (s, 3H); MS: m/z
266.1 (M+); Elemental analysis: C17H15NO2 Calcd.: C,
76.96; H, 5.70; N, 5.28; O, 12.06; found C, 77.13; H, 5.75;
N, 5.17; O, 12.01.2.2.5. Synthesis of 3-(bromomethyl)-2-chloroquinoline (4a)
Compound 3a was dissolved in DCM at 5 C, after 10–15 min
of stirring calculated amount of PBr3 was added drop wise
and the mixture was stirred at room temperature for 1 h.
The completion of the reaction was monitored by TLC. The
DCM was removed under vacuum and the reaction mass
was poured on ice cold water and the solution was neutralized
by adding saturated solution of NaHCO3. The solid thus
obtained was ﬁltered and recrystallized from ethyl acetate.
2.2.5.1. 3-(Bromomethyl)-2-chloroquinoline (4a). Yield 77%,
m.p. 129 C; IR-(KBr): 1670, 1630, 750 and 665 cm1; 1H
NMR-(CDCl3): d 8.25 (s, 1H), 8.16 (dd, 1H), 7.68 (dd, 1H),
7.40 (m, 1H), 7.52 (m, 1H), 4.47 (s, 2H); MS: m/z 257.4
(M+); Elemental analysis: C10H7BrClN: C, 46.82; H, 2.75;
N, 5.46; found C, 46.93; H, 2.81; N, 5.34.2.2.5.2. 2-(p-Tolyloxy)-3-(bromomethyl)-6-methylquinoline
(4i). Yield 76%, m.p. 151 C; IR-(KBr): 2930, 1624, 1560,
1150 and 675 cm1; 1H NMR-(CDCl3): d 8.05 (s, 1H), 7.61
(dd, 1H), 7.48 (s, 1H), 7.40 (dd, 1H), 7.23 (m, 2H), 7.16 (d,
2H), 4.74 (s, 2H), 2.46 (s, 3H), 2.38 (s, 3H); MS: m/z 343.1
(M+); Elemental analysis: C18H16BrNO Calcd.: C, 63.17; H,
476 P.G. Mandhane et al.4.71; N, 4.09; O, 4.68; found C, 63.31; H, 4.83; N, 3.96; O,
4.52.
2.2.5.3. Quinazolin-4(3H)-one (7). Yield, 93%, m.p. 215–
216 C; (Li et al., 2007). 1H NMR (DMSO-d6) d 7.53 (t, 1H,
J= 7.25 Hz), 7.67 (d, 1H, J= 8.15 Hz), 7.82 (m, 1H), 8.09–
8.13 (m, 2H), 12.24 (s, 1H, NH); GC–MS m/z 146 (M+).2.2.6. Synthesis of 3-((2-chloroquinolin-3-yl)methyl)quinazolin-
4(3H)-ones (8a)
To a mixture of 7 (1 eq.) and K2CO3 (1.2 eq.) in DMF, 4a
(1.2 eq.) was added and the reaction mixture was irradiated
under ultrasound irradiation for 5–10 min. The completion
of the reaction was monitored by TLC. After completion ice
cold water was added to the reaction mass and the solid
thus obtained was ﬁltered off and recrystallized from ethyl
acetate.
2.2.6.1. 3-((2-Chloroquinolin-3-yl)methyl)quinazolin-4(3H)-
one (8a). Yield 80%, m.p. 169 C; IR-(KBr): 1690, 1580,
1227 and 750 cm1; 1H NMR-(CDCl3): d 8.23 (s, 1H, Ar–
H), 8.11 (dd, 1H, Ar–H), 7.97 (dd, 1H, Ar–H), 7.93 (dd, 1H,
Ar–H), 7.88 (ddd, 1H, Ar–H), 7.71 (s, 1H, N–CH–N), 7.62
(ddd, 1H, Ar–H), 7.53 (ddd, 1H, Ar–H), 7.41 (dd, 2H, Ar–
H), 4.46 (s, 2H, CH2); MS: m/z 322.3 (M
+); Elemental analy-
sis: C18H12ClN3O Calcd.: C, 67.19; H, 3.76; N, 13.06; found:
C, 67.11; H, 3.71; N, 13.11.
2.2.6.2. 3-((2-Chloro-5-methylquinolin-3-yl)methyl)quinazolin-
4(3H)-one (8b). Yield 77%, m.p. 178 C; IR-(KBr): 1675,
1567, 1215 and 743 cm1; 1H NMR-(CDCl3): d 8.27 (s, 1H,
Ar–H), 8.10 (dd, 1H, Ar–H), 7.91 (dd, 1H, Ar–H), 7.73 (s,
1H, N–CH–N), 7.60 (dd, 1H, Ar–H), 7.51 (dd, 2H, Ar–H),
7.45 (dd, 1H, Ar–H), 7.39 (t, 1H, Ar–H), 4.53 (s, 2H, CH2),
2.51 (s, 3H, CH3); MS: m/z 336.1 (M
+); Elemental analysis:
C19H14ClN3O Calcd.: C, 67.96; H, 4.20; N, 12.51; found C,
67.91; H, 4.25; N, 12.46.
2.2.6.3. 3-((2-Chloro-6-methylquinolin-3-yl)methyl)quinazolin-
4(3H)-one (8c). Yield 71%, m.p. 129 C; IR-(KBr): 1683,
1561, 1231 and 731 cm1; 1H NMR-(CDCl3): d 8.29 (s, 1H,
Ar–H), 8.11 (dd, 1H, Ar–H), 7.93 (s, 1H, Ar–H), 7.86 (d,
1H, Ar–H), 7.81(s, 1H, N–CH–N), 7.58 (dd, 2H, Ar–H),
7.31 (d, 1H, Ar–H), 4.57 (s, 2H, CH2), 2.46 (s, 3H, CH3);
MS: m/z 336.3 (M+); Elemental analysis: C19H14ClN3O
Calcd.: C, 67.96; H, 4.20; N, 12.51; found C, 67.87; H, 4.29;
N, 12.44.
2.2.6.4. 3-((2-Chloro-7-methylquinolin-3-yl)methyl)quinazolin-
4(3H)-one (8d). Yield 80%, m.p. 182 C; IR-(KBr): 1687,
1575, 1225 and 741 cm1; 1H NMR-(CDCl3): d 8.25 (s, 1H,
Ar–H), 8.13 (d, 1H, Ar–H), 8.05 (dd, 1H, Ar–H), 7.92 (s,
1H, N–CH–N), 7.72 (ddd, 1H, Ar–H), 7.63 (s, 1H, Ar–H),
7.59 (d, 1H, Ar–H), 7.42 (dd, 2H, Ar–H), 4.51 (s, 2H, CH2),
2.49 (s, 3H, CH3); MS: m/z 336.4 (M
+); Elemental analysis:
C19H14ClN3O Calcd.: C, 67.96; H, 4.20; N, 12.51; found C,
67.90; H, 4.26; N, 12.53.
2.2.6.5. 3-((2-Chloro-7-methoxyquinolin-3-yl)methyl)quinazo-
lin-4(3H)-one (8e). Yield 84%, m.p. 127 C; IR-(KBr): 1696,
1577, 1231 and 731 cm1; 1H NMR-(CDCl3): d 8.13 (s, 1H,Ar–H), 8.07 (d, 1H, Ar–H), 7.94 (dd, 1H, Ar–H), 7.82 (s,
1H, N–CH–N), 7.71 (ddd, 1H, Ar–H), 7.53 (dd, 2H, Ar–H),
7.25 (d, 1H, Ar–H), 7.16 (s, 1H, Ar–H), 4.51 (s, 2H, CH2),
4.03 (s, 3H, OCH3); MS: m/z 352.2 (M
+); Elemental analysis:
C19H14ClN3O2 Calcd.: C, 64.87; H, 4.01; N, 11.94; found C,
64.81; H, 4.09; N, 11.90.
2.2.6.6. 3-((2-(p-Tolyloxy)-quinolin-3-yl)methyl)quinazolin-
4(3H)-one (8f). Yield 79%, m.p. 171 C; IR-(KBr): 1676,
1583, 1232 and 745 cm1; 1H NMR-(CDCl3): d 8.13 (dd, 1H,
Ar–H), 8.07 (dd, 1H, Ar–H), 7.93 (s, 1H, Ar–H), 7.86 (dd,
1H, Ar–H), 7.81 (ddd, 1H, Ar–H), 7.72 (s, 1H, N-CH-N),
7.61 (ddd, 1H, Ar–H), 7.54 (dd, 2H, Ar–H), 7.43 (ddd, 1H,
Ar–H), 7.21 (d, 2H, Ar–H), 7.01 (d, 2H, Ar–H), 4.50 (s, 2H,
CH2), 2.39 (s, 3H, CH3); MS: m/z 393.9 (M
+); Elemental anal-
ysis: C25H19N3O2 Calcd.: C, 76.32; H, 4.87; N, 10.68; found C,
76.21; H, 4.93; N, 10.71.
2.2.6.7. 3-((2-(p-Tolyloxy)-5-methylquinolin-3-yl)methyl)qui-
nazolin-4(3H)-one (8g). Yield 76%, m.p. 175 C; IR-(KBr):
1677, 1556, 1221 and 716 cm1; 1H NMR-(CDCl3): d 8.03
(dd, 1H, Ar–H), 7.89 (s, 1H, Ar–H), 7.70 (s, 1H, N-CH-N),
7.63 (ddd, 1H, Ar–H), 7.61 (dd, 1H, Ar–H), 7.53 (dd, 2H,
Ar–H), 7.41 (dd, 1H, Ar–H), 7.25 (dd, 1H, Ar–H), 7.05 (d,
2H, Ar–H), 7.89 (d, 2H, Ar–H), 4.51 (s, 2H, CH2), 2.37 (s,
6H, CH3); MS: m/z 407.6 (M
+); Elemental analysis:
C26H21N3O2 Calcd.: C, 76.64; H, 5.19; N, 10.31; found C,
76.51; H, 5.23; N, 10.39.
2.2.6.8. 3-((2-(p-Tolyloxy)-6-methylquinolin-3-yl)methyl)qui-
nazolin-4(3H)-one (8h). Yield 75%, m.p. 125 C; IR-(KBr):
1669, 1545, 1216 and 746 cm1; 1H NMR-(CDCl3): d 8.04
(dd, 1H, Ar–H), 7.94 (s, 1H, Ar–H), 7.89 (s, 1H, Ar–H),
7.81 (dd, 1H, Ar–H), 7.79 (s, 1H, N-CH-N), 7.57 (ddd, 1H,
Ar–H), 7.61, 7.45 (dd, 2H, Ar–H), 7.23 (d, 1H, Ar–H), 6.98
(d, 2H, Ar–H), 6.71 (d, 2H, Ar–H), 4.49 (s, 2H, CH2), 2.43
(s, 3H, CH3), 2.41 (s, 3H, CH3); MS: m/z 407.9 (M
+); Elemen-
tal analysis: C26H21N3O2 Calcd.: C, 76.64; H, 5.19; N, 10.31;
found C, 76.53; H, 5.21; N, 10.43.
2.2.6.9. 3-((2-(p-Tolyloxy)-7-methylquinolin-3-yl)methyl)qui-
nazolin-4(3H)-one (8i). Yield 82%, m.p. 188 C;IR-(KBr):
1688, 1584, 1234 and 746 cm1; 1H NMR-(CDCl3): d 8.16
(dd, 1H, Ar–H), 8.04 (d, 1H, Ar–H), 7.93 (s, 1H, Ar–H),
7.84 (s, 1H, N–CH–N), 7.71 (ddd, 1H, Ar–H), 7.62 (d, 1H,
Ar–H), 7.51 (s, 1H, Ar–H), 7.46 (dd, 2H, Ar–H), 6.91 (d,
2H, Ar–H), 6.75 (d, 2H, Ar–H), 4.51 (s, 2H, CH2), 2.41 (s,
3H, CH3), 2.39 (s, 3H, CH3); MS: m/z 408.1 (M
+); Elemental
analysis: C26H21N3O2 Calcd.: C, 76.64; H, 5.19; N, 10.31;
found C, 76.50; H, 5.27; N, 10.33.
2.2.6.10. 3-((2-(p-Tolyloxy)-7-methoxyquinolin-3-yl)methyl)-
quinazolin-4(3H)-one (8j). Yield 84%, m.p. 185 C; IR-(KBr):
1691, 1583, 1231 and 746 cm1; 1H NMR-(CDCl3): d 8.06 (dd,
1H, Ar–H), 7.94 (d, 1H, Ar–H), 7.76 (s, 1H, Ar–H), 7.74 (s,
1H, N–CH–N), 7.61 (ddd, 1H, Ar–H), 7.54 (dd, 2H, Ar–H),
7.35 (d, 1H, Ar–H), 7.23 (d, 2H, Ar–H), 7.03 (s, 1H, Ar–H),
6.75 (d, 2H, Ar–H), 4.52 (s, 2H, CH2), 3.91 (s, 3H, OCH3),
2.37 (s, 3H, CH3); MS: m/z 423.8 (M
+); Elemental analysis:
C26H21N3O3 Calcd.: C, 73.74; H, 5.00; N, 9.92; found C,
73.61; H, 5.07; N, 10.01.
NH2
O
OH NH2
HO
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In the present work, a series of quinazolinone derivatives were
synthesized via 3-(bromomethyl)-2-chloroquinoline or 2-(p-
tolyloxy)-(bromomethyl)quinoline 4a–j which has been synthe-
sized by reduction of 2-chloroquinoline-3-carbaldehyde or 2-
(p-tolyloxy)quinoline-3-carbaldehyde 2a–j in the presence of
the catalytic amount of NaBH4 and methanol yielding (2-chlo-
roquinolin-3yl)methanol or (2-(p-tolyloxy)quinolin-3yl)metha-
nol 3a–j. In the IR spectrum of compound 3a, a band in the
range of 2945 was obtained due to –OH stretching, as expected
for the formation of 3a–j. In the 1H NMR spectrum, the signal
was found at d 3.71 (singlet), which showed the presence of –
OH group. Compound 3a–j, on treatment with PBr3 in the
presence of DCM under ice cold condition, afforded 4a–j. In
the IR spectrum of 4a, a band in the range of 665 was obtained
due to C–Br stretching, as expected for the formation of 4a. In
the 1H NMR spectrum, the signal was found at d 4.47 (singlet),
which showed the presence of CH2–Br group (Scheme 1).
Secondly quinazolin-4(3H)-one 7 has been synthesized by
Nimentowiski reaction of Anthranilic 5 acid and Formamide
6 under the reﬂux temperature for 1 h. The structure of the
product was elucidated further on the basis of CONH group
in the compound, which caused a peak at 1620 cm1. In the
1H NMR spectrum, the characteristic proton of the CONH
group was observed at d 8.21 as a singlet (Scheme 2).
Finally 3-((2-chloroquinolin-3-yl)methyl)quinazolin-4(3H)-
one and 3-((2-(p-tolyloxy)quinolin-3-yl)methyl)quinazolin-
4(3H)-one 8a–j were synthesized by reacting quinazolin-
4(3H)-one 7 with various substituted 3-(bromomethyl)-2-chlo-
roquinoline or 2-(p-tolyloxy)-(bromomethyl)quinoline 4a–j in
the presence of K2CO3 in DMF under ultrasound irradiation
for 10–15 min. Formation of the compound was conﬁrmed
by 1H NMR spectrum, the characteristic proton of the N–
Ch2 group was observed at d 4.46 as a singlet (Scheme 3).
The synthesized compounds 8a–j was screened ‘‘in vitro’’
for antimicrobial activity. From the data presented in Tables
1 and 2, it is clear that compound 8b and 8g are highly active
against Bacillus subtilis (ATCC No. 6633), Staphylococcus aur-
eus (ATCC No. 25923), Salmonella typhimurium (ATCC No,
23564), Pseudomonas aeruginosa (ATCC No. 27853) as com-
pared to the standard (streptomycin and amphiciline). Other
compounds exhibit moderate to good antibacterial activity
against all organisms. Similarly, 8b and 8g exhibit good anti-
fungal activity against Candida albicans and Aspergillus fumig-N Cl
O p-Cresol
DMF,K 2CO3
R' = p-Cre
R1
R2
R3
R1
R2
R3
1
2
Schemeatus as compared to the standard drug used (ﬂuconazole). The
remaining compounds are moderately active against these two
micro-organisms (C. albicans and A. fumigatus). It can be con-
cluded that the antimicrobial activity of such compounds may
change by the introduction or elimination of a speciﬁc group.
3.1. In vitro antimicrobial screening
The antibacterial activities of the synthesized compounds 8a–j
were determined by the well-diffusion method (Ansari et al.,
2005). In this work, two Gram positive bacterial isolates, B.
subtilis (ATCC No. 6633), S. aureus (ATCC No. 25923), and
two Gram negative bacteria, S. typhimurium (ATCC No.
23564), P. aeruginosa (ATCC No. 27853) were used to investi-
gate the antibacterial activities. The antifungal activity was
screened against Candida albicans and Aspergillus fumigates
using Sabouraded dextrose agar medium. The bacterial liquid
cultures were prepared in infusion broth for their activity tests.
The compounds were dissolved in DMSO at concentration of
1 mg/ml. Antibacterial and antifungal activities of DMSO
against the test organisms were investigated, and were found
to be nil. Molten nutrient agar and Sabouraded dextrose agar
(15 cm3), kept at 45 C, were then poured into the Petri dishes
and allowed to solidify. Ten millimeter diameter holes were
then punched carefully using a sterile cork borer and com-
pletely ﬁlled with the test solutions. The plates were incubated
at 37 C for 24 and 48 h for antibacterial and antifungal activ-
ities, respectively. The inhibition zone that appeared around
the holes in each plate was measured. Activity was determined
by measuring the diameter of the inhibition zone and also the
minimal inhibitory concentration. Antibacterial activity of
each compound was compared with streptomycin and amphic-
iline (300 mg/ml) as standards, whereas ﬂuconazole (300 mg/
ml) was used in antifungal activity study. The observed zone
of inhibition for antibacterial and antifungal activities is pre-
sented in Tables 1 and 2, respectively.N R'
sol, -Cl
O
10-15 min, rt N R'
NaBH4, MeOH OH
PBr3, DCM,
1hrs, rt
N R'
Br
R1
R2
R3
R1
R2
R3
4
3
1
74(a-j) 8(a-j)
N
Br
R'
R3
R2
R1
N
NH
O
NaH, DMF
15-20 min rt N
N
O
NR'
R1
R2
R3
Scheme 3
Table 1 Antibacterial activity of tested compounds 8a–j.
Tested compounds B. subtilis ZIa (MIC)b S. aureus ZIa (MIC)b S. typhi ZIa (MIC)b P. aeroginosa ZIa (MIC)b
8a 13.2 (15) 13.5 (15) 14.8 (10) 14.5 (10)
8b 14.8 (10) 13.4 (10) 16.7 (05) 16.4 (05)
8c 14.3 (10) 14.1 (10) 12.8 (15) 12.7 (15)
8d 15.1 (10) 14.7 (10) 13.5 (15) 13.4 (15)
8e 14.8 (10) 14.6 (10) 12.9 (15) 12.8 (15)
8f 13.1 (15) 13.6 (15) 14.2 (10) 14.0 (10)
8g 15.4 (10) 15.7 (10) 16.5 (05) 16.3 (05)
8h 13.1 (15) 13.2 (15) 11.1 (20) 10.4 (20)
8i 14.1 (10) 14.6 (10) 12.2 (15) 12.5 (15)
8j 15.6 (10) 15.3 (10) 11.7 (15) 11.2 (15)
Streptomycin 15.1 (10) 14.9 (10) 16.4 (05) 16.1 (05)
Ampicilline 14.3 (10) 14.7 (10) 16.3 (05) 15.9 (05)
a Zone of inhibition.
b Minimum inhibitory concentration.
Table 2 Antifungal activity of compounds 8a–j.
Tested compounds C. albicans ZIa (MIC)b S. fumigatus ZI a(MIC)b
8a 13.6 (10) 12.1 (15)
8b 16.2 (05) 16.6 (05)
8c 13.8 (10) 13.2 (15)
8d 13.0 (10) 13.1 (15)
8e 14.1 (10) 12.2 (15)
8f 13.4 (10) 14.4 (10)
8g 16.8 (05) 16.5 (05)
8h 13.8 (10) 12.8 (15)
8i 13.4 (10) 14.2 (10)
8j 14.2 (10) 13.4 (20)
Fluconazole 16.4 (05) 16.5 (05)
a Zone of inhibition,
b Minimum inhibitory concentration.
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